Presented at #ESCCongress:
In older adults without cardiovascular disease, treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival. Full STAREE trial results: nej.md/4ghHPSC
@escardio

ALT Graphs from the Original Article "Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults." The trial name, STAREE, is in parentheses after the title. The graphs show the cumulative incidence of primary end-point events (death from cardiovascular causes, nonfatal myocardial infarction or stroke, or coronary revascularization, whichever occurred first). The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.
Just presented #ESC2026. In almost 10,000 healthy Australians age≥70, atorvastatin reduced major cardiovascular events by ~30%, but did not improve disability-free survival. Immensely grateful to the participants, GP investigators and STAREE team. bit.ly/45QXpzU
1
67
A/Prof Ingrid Hopper retweeted
New ESC 2026 Heart Failure Guidelines ♥️
📖 academic.oup.com/eurheartj/a…
A/Prof Ingrid Hopper retweeted
🚨BREAKING NEWS from #ESCCongress: The 2026 ESC Guidelines for the Management of Heart Failure are here, with major changes!🫀
Some of them:
📍HFrEF now includes LVEF <50%; HFmrEF has been removed
📍HFpEF is defined as LVEF ≥50%
📍“Acute HF” becomes “decompensated HF,” including acute or gradual deterioration requiring urgent treatment, even in an ambulatory setting
📍New treatment framework: Foundational Medical Therapy (FMT), Additional Medical Therapy (AMT) & Guideline-Directed Interventional Therapy (GDIT)
📍New decongestion strategy: urinary sodium-guided diuretic therapy may be considered (IIb B), while short-term acetazolamide or hydrochlorothiazide should be considered for persistent fluid overload despite loop diuretics (IIa B)
📍CRT recommendations remain broadly similar, but implantation may be planned earlier after FMT initiation
Read more: Https://doi.org/10.1093/eurh…
#ESCGuidelines #HeartFailure @escardio @jozinetm @h_arfsten @GTersalvi @DaniTomasoni_
Found my first abstract today, complete with Prof Henry Krum's handwritten edits. At the time I saw corrections; now I see mentorship. Grateful for everything he taught me.
1
39
Therapeutic Guidelines immune compromise is also available to view, presented at ASID, which I was also fortunate to chair. My thanks to all the contributors for their expertise and generosity. bit.ly/4wQEZLD
32
Therapeutic Guidelines Antibiotic surgical prophylaxis were presented at ASID, and are now available to view on TG Youtube channel. I was privileged to chair this guideline, working alongside an outstanding multidisciplinary writing group. bit.ly/4xdfTpV
@Monash_SPHPM
38
Older adults with heart failure are increasingly cared for at home—but what does that care actually look like? Our real-world evaluation takes a look at caring for older, multimorbid patients beyond the hospital. bit.ly/4haFH1f @AlfredHealth @Monash_SPHPM
20
A/Prof Ingrid Hopper retweeted
Influenza update 📢 New REMAP-CAP data: oseltamivir shows no benefit, and possible harm, in critically ill patients ≥12 yrs. Guidance updated. 🔗 bit.ly/4btiGmi and🔗bit.ly/4vEFwhX
#Influenza #CriticalCare
Delighted to see this go live. Timely, transparent evidence synthesis is essential as new severe influenza trial data emerge. Open for public review. livingevidence.org.au/influe… @Monash_SPHPM @AlfredHealth
30
Here's a wonderful study by my PhD student Dr Swarna Vishwanath with international collaborators at the UK Twin registry showing that twin-pair factors (genetics & environment) have greater impact on cognition than CV risk factors. bit.ly/3SfCUJJ
1
1
63
Work participation after heart or lung transplant is a key priority. Read what factors are associated with return to work after cardiothoracic transplant here. bit.ly/4npatEm
27
Update for GPs "Treating comorbidities in heart failure: tackling the hidden burden". bit.ly/4o9AMyg The Medicine Today Group offers free online subscriptions to all health and medical practitioners registered with AHPRA. Log in to access. @Monash_SPHPM @AlfredHealth
43
Does the pneumococcal polysaccharide vaccine prevent heart attacks and strokes? Read our RCT investigating this here. bit.ly/4pCg6ji @Monash_SPHPM @AlfredHealth
39
Read an overview of our current understanding of the impact of obesity on the development of HFpEF and an outline of the approach to diagnosis and new therapeutic options. bit.ly/47KfK3N
@Monash_SPHPM @AlfredHealth
33
Fantastic research in the Pacific Islands presented in Suva today. Addressing issues faced by a young population at risk of communicable and non-communicable disease, as well as impacts of climate change.
30
New 2025 heart failure guidelines released by iCARDIO (International CARDIO Alliance to Improve Disease Outcomes). Global representation, considers resource availability, succinct. @Monash_SPHPM @AlfredHealth pubmed.ncbi.nlm.nih.gov/4053…
38
A/Prof Ingrid Hopper retweeted
Heart failure symptoms can be hard to recognise, so it's vital to know the signs, including breathlessness 🫁, fatigue🥱, swelling🎈& weight gain⚖️. Take control of your heart health. Talk to your GP. Visit hearts4heart.org.au
#Hearts4heart #HFAW #HeartFailure #Comorbidities
A/Prof Ingrid Hopper retweeted
Over 100 expert group members contributed to the recent release of the #Antibiotic #guidelines. These incredible #experts come from across #Australia to ensure the recommendations are representative of practice nationwide.
We acknowledge and thank these contributors, many of whom are leaders in their therapeutic area, for supporting the delivery of this crucial resource. View our wonderful Antibiotic Expert Group members: bit.ly/3TDlZOs
STAREE-HEART is an ancillary study of the STAtins in Reducing Events in the Elderly (STAREE) study, supported the NHMRC. Here's the protocol and baseline description of participants. @Monash_SPHPM @AlfredHealth bit.ly/4l0SJg8
1
30














